Age-Related Macular Degeneration (AMD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Ranibizumab Biosimilar Shows Equivalent Efficacy to Branded Drug for Neovascular AMD Ranibizumab Biosimilar Shows Equivalent Efficacy to Branded Drug for Neovascular AMD
In a phase 3 study, the ranibizumab biosimilar SB11 demonstrated equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab for patients with neovascular age-related macular degeneration (nAMD).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 1, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa
RARITAN, N.J., November 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new 12-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for inherited retinal disease X-linked retinitis pigmentosa (XLRP). The data showed that low and intermediate doses were well-tolerated and continued to demonstrate statistically significant sustained or increased vision improvement across multiple metrics (mean sensitivity, volumetric and pointwise) and modalities (full-field static perimetry and microperimetry). Data on the novel adeno-associated virus retini...
Source: Johnson and Johnson - November 13, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Vitamin D3, Omega-3 Fatty Acids Have No Impact on AMD
FRIDAY, Oct. 30, 2020 -- For initially healthy men and women, supplementation with vitamin D3 and marine omega-3 fatty acids have no significant impact on age-related macular degeneration (AMD) incidence or progression, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 30, 2020 Category: Pharmaceuticals Source Type: news

Anti-VEGF Therapy May Aid Visual Acuity in Some nAMD Patients
MONDAY, Oct. 19, 2020 -- For about 20 percent of patients with neovascular age-related macular degeneration (nAMD), useful visual acuity (VA) is preserved with anti-vascular endothelial growth factor (VEGF) treatment, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 19, 2020 Category: Pharmaceuticals Source Type: news

For Some, Anti-VEFG Treatment Preserves Sight for a Lifetime For Some, Anti-VEFG Treatment Preserves Sight for a Lifetime
Nearly 20% of those who received anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) retained useful visual acuity over their lifetime, a new study finds.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 17, 2020 Category: Pathology Tags: Ophthalmology News Source Type: news

Changes to Anti-VEGF Protocols Questioned in Wet AMD Changes to Anti-VEGF Protocols Questioned in Wet AMD
New research calls into question the benefit of newer injection schedules to prevent vision loss in neovascular age-related macular degeneration.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 14, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Implant Reduces Treatment Burden in Wet Macular Degeneration Implant Reduces Treatment Burden in Wet Macular Degeneration
The administration of ranibizumab with an implant, rather than intravitreal injection, looks promising for neovascular age-related macular degeneration, interim results from a phase 3 study indicate.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 13, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Visible Genomics hires clinical advisers to prep for macular degeneration test
The company is preparing to launch a non-invasive genetic eye test that can determine a patient's likelihood of contracting age-related macular degeneration. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 28, 2020 Category: Biotechnology Authors: I-Chun Chen Source Type: news

Parkinson's Drug Levodopa Eyed as Treatment for Severe Macular Degeneration
WEDNESDAY, Sept. 16, 2020 -- A drug long used to treat Parkinson ' s disease may benefit patients with a severe form of age-related macular degeneration (AMD), a small clinical trial suggests. One of the leading causes of vision loss in older people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 16, 2020 Category: General Medicine Source Type: news

Levodopa Benefits Neovascular Age-Related Macular Degeneration
TUESDAY, Sept. 15, 2020 -- Levodopa is a safe and well-tolerated treatment for neovascular age-related macular degeneration (nAMD) and improves visual outcomes, according to a study recently published in The American Journal of Medicine. Anna G.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2020 Category: Pharmaceuticals Source Type: news

Levodopa may improve vision in patients with macular degeneration
(Elsevier) Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized and improved their vision. It reduced the number of treatments necessary to maintain vision, and as such, will potentially reduce the burden of treating the disease, financially and otherwise. Their findings appear in The American Journal of Medicine, published by Elsevier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

RegenxBio is growing — and pushing its eye disease treatment through yet another clinical trial
The Rockville biotech is trying to change the game for patients with wet age-related macular degeneration and diabetic retinopathy. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 27, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news

Artificial intelligence recognizes deteriorating photoreceptors
(University of Bonn) A software based on artificial intelligence (AI), which was developed by researchers at the Eye Clinic of the University Hospital Bonn, Stanford University and University of Utah, enables the precise assessment of the progression of geographic atrophy (GA), a disease of the light sensitive retina caused by age-related macular degeneration (AMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2020 Category: International Medicine & Public Health Source Type: news

Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit-risk pr...
Source: Roche Media News - July 22, 2020 Category: Pharmaceuticals Source Type: news

Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit-risk pr...
Source: Roche Investor Update - July 22, 2020 Category: Pharmaceuticals Source Type: news